Dr. Khurram Bashir
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 161
Licensed in Alabama since 1997, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AL license 20449 (first issued 1997; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
- Huntsville Hospital Huntsville, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 161
- Services billed
- 410
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 140 | 97 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 72 | 22 |
| Hospital discharge day management, 30 minutes or less | 24 | 22 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Birmingham, AL | 201 |
| Baclofen Other prescribers in Birmingham, AL | 171 |
| Kesimpta Pen (ofatumumab) | 143 |
| Dimethyl Fumarate | 120 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Birmingham, AL | 95 |
| Carbamazepine Other prescribers in Birmingham, AL | 90 |
| Pregabalin Other prescribers in Birmingham, AL | 87 |
| Betaseron (interferon beta-1b) | 85 |
| Zolpidem Tartrate Other prescribers in Birmingham, AL | 84 |
| Mayzent (siponimod) | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $458,439 in research payments for these studies, mostly to the institutions running them.
- An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
Celgene Corporation - Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Genzyme Corporation · Completed · NCT04410978 - A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06220201
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.